Regeneron Pharmaceuticals, Inc. (REGN) Stock Price & Analysis
Regeneron Pharmaceuticals, Inc. (REGN) closed at USD 819.09 on Thursday, October 22, 2026, up 1.67% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 805.67; the Oct 22, 2026 session ranged USD 800–825.52 on volume of 852,286 shares. Market capitalization is $84.33B, with a 52-week range of USD 572.75–859.34 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/REGN.md
Key facts (REGN)
- Last four reported quarters (through Jun 30, 2026): revenue $15.5B, net income $4.33B (27.9% margin), free cash flow $3.76B (SEC filings).
- Valuation: P/E 19.5x (avg 20.8x at the last 3 fiscal year-ends), EV/EBITDA 17.9x, net cash $6.01B.
- Earnings quality: non-operating income $1.32B vs operating income $3.84B over the last four quarters; P/E excluding non-operating income ≈26.2x (estimate: non-operating income taxed at the company's 16.2% effective rate).
- 3 of 80 tracked superinvestors hold REGN (13F, Q2 2026): 0 new, 2 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $6.7M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +43.0% vs S&P 500 +14.9%; 5Y +44.5% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 16.2, revenue estimate $4.56B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (REGN)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B | $15.5B |
| Operating income | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B | $3.84B |
| Net income | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B | $4.33B |
| EPS (diluted) | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 | — |
| Free cash flow | $6.53B | $4.42B | $3.88B | $3.66B | $4.08B | $3.76B |
| Operating margin | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% | 24.7% |
| Net margin | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% | 27.9% |
| Revenue growth | +89.1% | -24.3% | +7.8% | +8.3% | +1.0% | — |
| Cash + short-term investments | $5.69B | $7.74B | $10.8B | $9.01B | $8.61B | — |
| Total debt | $1.98B | $1.98B | $1.98B | $1.98B | $1.99B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (REGN)
P/E 19.5x · P/E ex non-operating (est.) ≈26.2x · P/S 5.4x · EV/EBITDA 17.9x · EV/Sales 5.0x · P/FCF 22.4x · P/B 2.7x · FCF yield 4.46% · Earnings yield 5.13% · Dividend yield (paid, TTM) 0.45% · Buyback yield (TTM) 3.91% · Net cash $6.01B · EV $78.3B
P/E at fiscal year-ends: Dec 2025 18.6x, Dec 2024 18.6x, Dec 2023 25.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (REGN)
3 of 80 tracked investors hold REGN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Mason Hawkins | Southeastern Asset Management | 4.95% | $95.0M | Added +16.6% |
| Harry Burn | Sound Shore | 2.44% | $79.2M | Reduced -15.9% |
| Dodge & Cox Funds | Dodge & Cox | 1.59% | $3.04B | Added +9.3% |
Insider sales (SEC Form 4, open-market, last ~7 months) (REGN)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Murphy Andrew J | Co-Chief Scientific Officer | 4,147 | $3.2M | 7.4% | Yes (adopted May 7, 2026) | Too little history (no open-market trades in 2025) |
| 2026-09-02…2026-09-03 | McCourt Marion | EVP Commercial | 2,346 | $2.0M | 16.1% | Yes (adopted February 17, 2026) | Too little history (no open-market trades in 2025) |
| 2026-09-02 | Guarini Kathryn | Director | 400 | $340K | 39.9% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-10 | Guarini Kathryn | Director | 400 | $320K | 39.9% | Yes (adopted February 13, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-10 | Zoghbi Huda Y | Director | 800 | $640K | 32% | Yes (adopted November 20, 2025) | Too little history (no open-market trades in 2025) |
| 2026-07-02 | Ryan Arthur F | Director | 200 | $130K | 1.1% | Yes (adopted October 31, 2025) | Too little history (no open-market trades in 2025) |
| 2026-05-01 | Ryan Arthur F | Director | 100 | $71K | 0.6% | Yes (adopted October 31, 2025) | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (REGN)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | TD Cowen | Target raised | Buy | $960 → $980 |
| 2026-10-19 | Piper Sandler | Target raised | Overweight | $854 → $865 |
| 2026-10-15 | UBS | Upgrade | Neutral → Buy | $660 → $978 |
| 2026-10-08 | RBC Capital | Target raised | Sector Perform | $737 → $810 |
| 2026-10-07 | Truist Securities | Target raised | Buy | $772 → $780 |
| 2026-10-07 | Morgan Stanley | Target raised | Equal-Weight | $758 → $779 |
| 2026-10-06 | JP Morgan | Target raised | Overweight | $900 → $950 |
| 2026-10-01 | Jefferies | Target raised | Buy | $870 → $930 |
| 2026-10-01 | Argus Research | Upgrade | Hold → Buy | $850 |
| 2026-09-29 | RBC Capital | Reiterated | Sector Perform | $737 |
| 2026-09-10 | HSBC | Target raised | Buy | $800 → $920 |
| 2026-08-17 | Leerink Partners | Target raised | Market Perform | $641 → $824 |
Total return (dividends reinvested) (REGN)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +43.0% | +44.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +43.2% | +7.6% |
| Volatility (annualized) | 32.9% | 31.7% |
| Max drawdown | -25.9% (Jan 2026→Jun 2026) | -59.0% (Aug 2024→May 2025) |
REGN revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Collaboration revenue | $2.46B | 57.2% | +31.9% |
| Net product sales | $1.64B | 38.3% | +0.7% |
| Libtayo | $489.4M | 11.4% | +30.0% |
| Other revenue | $193.3M | 4.5% | +5.1% |
| Lynozyfic | $16.5M | 0.4% | — |
| Total revenue | $4.29B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
REGN suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Bayer | “•the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated;” |
| Partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | “See the "Collaboration, License, and Other Agreements" section below for descriptions of our agreements with Alnylam Pharmaceuticals, Inc. and Intellia Therapeutics, Inc.” |
| Partner | Intellia Therapeutics, Inc. (NTLA) | “See the "Collaboration, License, and Other Agreements" section below for descriptions of our agreements with Alnylam Pharmaceuticals, Inc. and Intellia Therapeutics, Inc.” |
| Partner | Hansoh Pharmaceuticals Group Company | “In July 2025, our license agreement with Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights outside of mainland China, Hong Kong, and Macau for HS-20094 (a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical development in China) became effective.” |
| Partner | Tessera Therapeutics | “In January 2026, our collaboration agreement with Tessera Therapeutics, Inc. to develop and commercialize TSRA-196 (Tessera's investigational program for the treatment of alpha-1 antitrypsin deficiency ("AATD")) became effective.” |
| Competitor | Merck (MRK) | “There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda® (pembrolizumab), Bristol-Myers Squibb's Opdivo® (nivolumab), Roche's Tecentriq® (atezolizumab), AstraZeneca's Imfinzi® (durvalumab), and Sun Pharma's Unloxcyt™ (cosibelimab).” |
Quoted from the company's 10-K filed Feb 4, 2026.
Companies that name REGN in their SEC reports
| Relationship to REGN | Company | Filing | Sentence |
|---|---|---|---|
| partner | Celularity Inc (CELU) | 10-K Apr 30, 2026 | “August 25, 2023, the Company entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc.” |
| partner | Allarity Therapeutics, Inc. (ALLR) | 10-K Mar 30, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” |
| customer | MAIA Biotechnology, Inc. (MAIA) | 10-K Mar 23, 2026 | “In February 2021, we signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, which represents a significant” |
| partner | Cellectis S.A. (CLLS) | 20-F Mar 20, 2026 | “Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron Pharmaceuticals Inc., Fate Therapeutics Inc., CRISPR Therapeutics Inc., Caribou Biosciences Inc., Takeda Pharmaceutical Company Limited, Mustang Bio, Atara Biotherapeutics Inc., Adaptimmune (in collaboration with Astellas), Poseida Therapeutics Inc. (acquired by F.” |
| partner | Inhibrx Biosciences, Inc. (INBX) | 10-K Mar 19, 2026 | “License fee revenue during the year ended December 31, 2024 was $0.2 million and consisted of revenue related to our license agreement with Regeneron Pharmaceuticals, Inc., which we recognized following the grant of two six-month extensions of the option term during the year, each for revenue of $0.1 million.” |
| partner | CytomX Therapeutics, Inc. (CTMX) | 10-K Mar 16, 2026 | “A key focus of our current work with collaboration partners is T-cell engaging bispecific therapies ("TCEs") where we have significant ongoing efforts with partners such as Bristol Myers Squibb and Regeneron and maintain significant research expertise.” |
| partner | Pioneer Bancorp, Inc./MD (PBFS) | 10-K Mar 12, 2026 | “Large employers in the Capital Region include GE Vernova, Regeneron Pharmaceuticals, Inc., GlobalFoundries, Albany Med Health System, St. Peter's Health Partners, Northeast Grocery Inc., Rensselaer Polytechnic Institute and the State of New York.” |
| partner | Adicet Bio, Inc. (ACET) | 10-K Mar 12, 2026 | “If our collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) is terminated, or if Regeneron materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition would be materially harmed.” |
| partner | BioNTech SE (BNTX) | 20-F Mar 10, 2026 | “(10)In collaboration with Regeneron.” |
| partner | BridgeBio Oncology Therapeutics, Inc. (BBOT) | 10-K Mar 5, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme and Roche.” |
| partner | Nuvation Bio Inc. (NUVB) | 10-K Mar 2, 2026 | “There are many other companies that have commercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” |
| customer | Biohaven Ltd. (BHVN) | 10-K Mar 2, 2026 | “In May 2024, we announced that we entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron") under which we will sponsor and fund the planned combination Phase 1/2 clinical trial, and Regeneron will provide Libtayo.” |
| partner | Intellia Therapeutics, Inc. (NTLA) | 10-K Feb 26, 2026 | “Our technological advancements and any potential for revenue may be derived in part from our collaborations, including, for example, with Regeneron Pharmaceuticals, Inc. ("Regeneron"), and if the collaboration or co-development agreements related to a material collaboration were to be terminated or materially altered in an adverse manner, our business, financial condition, results of operations and prospects would…” |
| partner | OPKO HEALTH, INC. (OPK) | 10-K Feb 26, 2026 | “This includes advancing our internal candidates and progressing our clinical collaborations with Merck Sharp & Dohme LLC ("Merck") and Regeneron Pharmaceuticals, Inc. ("Regeneron").” |
| partner | Arcus Biosciences, Inc. (RCUS) | 10-K Feb 25, 2026 | “There are many other companies that have commercialized and/or are developing oncology treatments for cancer including large pharmaceutical and biotechnology companies such as AstraZeneca, BeiGene, Ltd. ("BeiGene"), The Bristol-Myer Squibb Company ("Bristol-Myers Squibb"), GlaxoSmithKline plc ("GSK"), Merck, Novartis Inc. ("Novartis"), Pfizer Inc. ("Pfizer"), Regeneron Pharmaceuticals, Inc. ("Regeneron") in partne…” |
REGN customer concentration
In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (45%, 32%) of revenue, per the company's 10-Q filed Jul 30, 2026. The company does not name them.
REGN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $16.20 | $13.21 | +22.7% | $4.56B | 23 |
| Next quarter (ends Dec 2026) | $20.44 | $12.92 | +58.2% | $5.27B | 20 |
| Current fiscal year (ends Dec 2026) | $59.13 | $45.85 | +29.0% | $17.60B | 28 |
| Next fiscal year (ends Dec 2027) | $52.03 | $47.40 | +9.8% | $18.59B | 9 |
Key Statistics (as of October 23, 2026 at 09:22 UTC)
| Price | USD 819.09 |
|---|---|
| Change | ▲ 1.67% (up) |
| Previous Close | USD 805.67 |
| Open | USD 809.72 |
| Day Range | USD 800 – 825.52 |
| 52-Week Range | USD 572.75 – 859.34 |
| Volume | 852,286 shares |
| Market Cap | $84.33B |
| Exchange | NMS |
Technical Analysis (REGN)
Nexqual's technical model rates REGN "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.05 (neutral) |
| vs SMA50 | Above (USD 791.39) |
| MACD | 7.17 (positive) |
Earnings (REGN)
| Next Earnings Date | 2026-10-30 |
|---|---|
| EPS Estimate | USD 16.2 |
| Revenue Estimate | $4.56B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 14.29 vs est 10.21 ▲ beat |
| 2026-03-31 | USD 9.47 vs est 8.9 ▲ beat |
| 2025-12-31 | USD 11.44 vs est 10.75 ▲ beat |
| 2025-09-30 | USD 11.83 vs est 9.64 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Financials & Fundamentals (REGN)
| Total Revenue | $15.53B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +16.70% |
| Gross Margin | +44.46% |
| Operating Margin | +33.11% |
| Profit Margin | +27.87% |
| ROE | +14.04% |
| Debt / Equity | 0.09 |
| Current Ratio | 3.34 |
| Total Cash | $7.99B |
| Total Debt | $2.71B |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Ownership (REGN)
| Insider Ownership | +2.08% |
|---|---|
| Institutional Ownership | +93.30% |
| Shares Outstanding | 101.14M |
| Float | 95.85M |
| Short % of Float | +2.21% |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
From Regeneron Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-04)
Key Strengths & Strategy (as disclosed to the SEC)
- The conduct of clinical trials is subject to extensive regulation, including compliance with the FDA's bioresearch monitoring regulations and Good Clinical Practice requirements ("GCPs"), which establish standards for recruiting for, conducting, recording data from, and reporting the results of, clinical trials, and are intended to assure that the data and reported results are credible, representative, and accurate, and that the rights, safety, and well-being of study participants are protected.
- Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities.
- In-licensing a late-stage GLP-1/GIP agonist enables us to study combinations with our products and product candidates in order to address muscle loss and potentially other comorbidities of obesity, such as cardiovascular diseases, diabetes, and liver conditions.
Partnerships
- In January 2025, RGC entered into an agreement with Truveta Inc. pursuant to which RGC will sequence exomes and conduct genotyping and imputation of up to ten million de-identified consented volunteers using biospecimens provided by Truveta health system members across the United States.
- In July 2025, our license agreement with Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights outside of mainland China, Hong Kong, and Macau for HS-20094 (a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical development in China) became effective.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued development of such candidates and/or receipt of regulatory approval or commercial sale.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRNA | Moderna, Inc. | USD 202.63 | ▼ 17.57% |
| ARGX | argenx SE | USD 875.76 | ▼ 1.61% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 535.17 | ▲ 2.03% |
| ONC | BeOne Medicines Ltd. | USD 382.27 | ▼ 1.08% |
| RVMD | Revolution Medicines, Inc. | USD 187.69 | ▼ 3.39% |
| RPRX | Royalty Pharma plc | USD 63.75 | ▲ 2.57% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt